ET 0038
Alternative Names: ET-0038Latest Information Update: 28 Jun 2025
At a glance
- Originator Shanghai ETERN Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non-receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours in China (PO)
- 28 Jun 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 01 Sep 2022 Shanghai ETERN BioPharma plans a phase I FIRST clinical trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, in November 2022 (PO, Capsule) (NCT05525559)